David M. Charytan

Jun 24, 2024 | nature.com | Peter Rossing |David M. Charytan |José Luis Gorriz |Linong Ji |Roland E. Schmieder

AbstractPeople with type-2-diabetes (T2D) and chronic kidney disease (CKD), have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) independently reduce cardiovascular and kidney events. The effect of combining both is unclear.

Jun 13, 2023 | drc.bmj.com | David M. Charytan |Kenneth W. Mahaffey |Meg Jardine |Christopher Cannon

DiscussionIn this post hoc analysis of the CREDENCE study, we demonstrated that the glycemic effects of canagliflozin were modified by baseline eGFR, with a progressively lesser reduction and lower likelihood of achieving a >0.5% decrease in HbA1c across CKD stages G1-2 (eGFR >60 mL/min/1.73 m2), stage G3A (eGFR 45–60 mL/min/1.73 m2), and stage 3B (eGFR 30–44 mL/min/1.73 m2).